The AYON launch is gaining meaningful traction, driving both top-line growth and margin improvement. With guidance implying sustained momentum and a path toward profitability, traders should monitor upcoming quarterly execution and potential FDA clearance for AYON's power liposuction expansion in mid-2026 as a catalyst.
Price Chart
Executive Summary
Apyx Medical reported record Q4 2025 revenue of $19.2 million, up 34.7% year-over-year, driven by strong U.S. demand for its AYON Body Contouring System. The company achieved positive adjusted EBITDA of $0.7 million in the quarter and narrowed its net loss significantly. It also issued FY2026 revenue guidance of $57.5M–$58.5M, representing 9–11% growth, supported by continued AYON adoption.
Key Financial Metrics
Key Facts
- Q4 2025 total revenue: $19.2 million, up 34.7% YoY from $14.2 million
- Surgical Aesthetics revenue: $16.7 million (+38.1% YoY), driven by U.S. AYON launch
- OEM revenue: $2.5 million (+15.6% YoY)
- Net loss narrowed to $1.3 million from $4.6 million in Q4 2024
- Adjusted EBITDA turned positive at $0.7 million vs. $2.2 million loss in prior year
- FY2026 revenue guidance: $57.5M–$58.5M (vs. $52.8M in FY2025)
- Surgical Aesthetics guidance: $53.0M–$54.0M; OEM expected to decline to ~$4.5M
- Cash balance: $31.7 million; management expects runway into 2027
Financial Impact
Revenue growth accelerating with 34.7% Q4 YoY increase and 9–11% full-year 2026 guidance. Adjusted EBITDA improved by $2.9M YoY in Q4. Operating expenses held flat despite growth.
Risk Factors
- OEM revenue is expected to decline further to ~$4.5M in 2026, reducing diversification
- Future growth dependent on continued AYON adoption; any slowdown could impact guidance
- FDA clearance for power liposuction label expansion expected mid-2026 — risk of delay
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252607 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $2.41 | awaiting T+20 | — | $2.46 (+2.07%) |
Aug 7, 2026 11w ago | 8-K | $3.46 $3.05 | ▼ −11.85% | ▼ −10.94% | $2.46 (−28.90%) |
May 21, 2026 22w ago | 8-K | $4.13 $3.95 | ▼ −4.36% | ▼ −2.94% | $2.46 (−40.44%) |
May 21, 2026 22w ago | Press Release | $4.25 $4.04 | ▼ −4.94% | ▼ −5.27% | $2.46 (−42.12%) |
May 14, 2026 23w ago | 8-K | $4.36 $4.69 | ▲ +7.57% | ▲ +8.43% | $2.46 (−43.58%) |
May 11, 2026 24w ago | 8-K | $3.92 $4.86 | ▲ +23.98% | ▲ +24.28% | $2.46 (−37.24%) |
Apr 23, 2026 26w ago | Press Release | $3.80 $3.79 | ▼ −0.26% | ▼ −4.90% | $2.46 (−35.26%) |
Mar 10, 2026 32w ago | Press Release | $3.45 $3.81 | ▲ +10.43% | ▲ +10.59% | $2.46 (−28.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers